The U.S. International Trade Commission (ITC) will begin an investigation into Eli Lilly’s complaint that Hospira Inc. and affiliated pharmaceutical companies infringed on Lilly’s patent by importing and selling generic versions of the cancer drug, Gemzar®. The complaint was first filed after Hospira launched a generic version of Lilly’s Gemzar®. The ITC will look into whether Hospira and the other companies have violated section 337 of the Tariff Act of 1930, which restrict importing infringing products. Lilly is represented by Finnegan.
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.